caffeine has been researched along with Basal Ganglia Diseases in 6 studies
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "HP produced a full blown catalepsy, akinesia and a significant impairment in locomotion and antioxidant status." | 1.48 | Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice. ( Anoopkumar-Dukie, S; Arora, D; Grant, GD; Hall, S; Kinra, M; Mallik, SB; Mudgal, J; Nampoothiri, M; Rao, CM, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, D | 1 |
| Mudgal, J | 1 |
| Nampoothiri, M | 1 |
| Mallik, SB | 1 |
| Kinra, M | 1 |
| Hall, S | 1 |
| Anoopkumar-Dukie, S | 1 |
| Grant, GD | 1 |
| Rao, CM | 1 |
| Kakihara, S | 1 |
| Yoshimura, R | 1 |
| Shinkai, K | 1 |
| Matsumoto, C | 1 |
| Goto, M | 1 |
| Kaji, K | 1 |
| Yamada, Y | 1 |
| Ueda, N | 1 |
| Ohmori, O | 1 |
| Nakamura, J | 1 |
| Caroff, S | 1 |
| Rosenberg, H | 1 |
| Gerber, JC | 1 |
| Zahniser, NR | 1 |
| Simosky, JK | 1 |
| Mayfield, RD | 1 |
| Negri, CA | 1 |
| Hanania, T | 1 |
| Larson, GA | 1 |
| Kelly, MA | 1 |
| Grandy, DK | 1 |
| Rubinstein, M | 1 |
| Low, MJ | 1 |
| Fredholm, BB | 1 |
| Goff, DC | 1 |
| Henderson, DC | 1 |
| Amico, E | 1 |
| Panchenko, EN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial Administering Estradiol Patch vs. Placebo Patch as add-on to Antipsychotics in Female Patients Above the Age of 38 With Schizophrenia, Schizoaffective or Schizophreniform Disorder[NCT04093518] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-12-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for caffeine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catalepsy; Cyclooxygenase Inhibitor | 2018 |
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catecholamines; Cen | 2005 |
Neuroleptic malignant syndrome and malignant hyperthermia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Fever; Fluphenazine; Halothane; Humans; Musc | 1983 |
Functional uncoupling of adenosine A(2A) receptors and reduced responseto caffeine in mice lacking dopamine D2 receptors.
Topics: Animals; Basal Ganglia Diseases; Caffeine; Cyclic AMP; Female; gamma-Aminobutyric Acid; Globus Palli | 2000 |
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Ambulatory Care; Analysis of Variance; Basal Ganglia Di | 1992 |
[Treatment of extrapyramidal hyperkinesis].
Topics: Adolescent; Adult; Ambulatory Care; Basal Ganglia Diseases; Benzimidazoles; Benzyl Compounds; Bromin | 1973 |